Hexvix, A Diagnostic Drug for Bladder Cancer of Asieris, Completed the First Patient Dose in Phase III Trial Read more
Reaction Biology and Vyant Bio Announce Closing of Definitive Agreement to Acquire U.S. Operations of Vyant Bio, Inc. Subsidiary Read more
European Commission grants first approval worldwide of Beyfortus (nirsevimab) for prevention of RSV disease in infants Read more
NKGen Biotech Announces Collaboration with the Parkinson’s Foundation to Bring Its Novel Natural Killer Cell Therapy to the Clinic for Advanced Parkinson’s Disease Read more
BeiGene Receives European Commission Approval for BRUKINSA (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma Read more
REITHERA EXPANDS LARGE-SCALE VIRAL VECTOR PRODUCTION CAPABILITIES WITH OPENING OF NEW MANUFACTURING FACILITY Read more
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline Read more